STOCKHOLM, Nov. 7, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") contiguous announced that it volition big a Key Opinion Leader (KOL) Fireside Chat connected the IgA Nephropathy (IgAN) attraction scenery successful the US connected Tuesday, November 8th, 2022 astatine 1:30pm Eastern Time.
The fireside chat volition diagnostic a presumption from KOL Richard Lafayette, M.D., F.A.C.P., Stanford Healthcare, who volition sermon the value of proteinuria reduction, the precocious published information from Part A of the NefIgArd study, and the existing attraction paradigm successful the United States for IgAN patients. A unrecorded Q&A league volition travel the ceremonial presentations.
To register, delight click here.
Dr. Lafayette is Professor of Medicine (Nephrology) and the Found and Director of the Stanford Glomerular Disease Center and its fellowship grooming programme astatine Stanford University Medical Center. His 25-year vocation successful nephrology spans wide nephrology, transplant nephrology, and focuses connected glomerular disease. During this time, helium has served arsenic Senior Associate Chair of Medicine for six years and Clinical Chief of Nephrology for much than a decade. Dr. Lafayette was a subordinate of the archetypal Kidney News Editorial Board and is simply a subordinate of the ASN Glomerular Diseases Advisory Group. He earned his aesculapian grade astatine New York Medical College, trained successful Internal Medicine astatine Long Island Jewish Medical Center and successful nephrology astatine Stanford University.
For further information, delight contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The accusation was sent for publication, done the bureau of the interaction persons acceptable retired above, connected November 7, 2022 astatine 9:00 a.m. CET.
About Calliditas
Calliditas Therapeutics is simply a commercialized signifier biopharma institution based successful Stockholm, Sweden focused connected identifying, processing and commercializing caller treatments successful orphan indications, with an archetypal absorption connected renal and hepatic diseases with important unmet aesculapian needs. Calliditas' pb product, developed nether the sanction Nefecon, has been granted accelerated support by the FDA nether the commercialized sanction TARPEYO® and conditional selling authorization by the European Commission nether the commercialized sanction KINPEYGO®. KINPEYGO is being commercialized successful the European Union Member States by Calliditas' partner, STADA Arzneimittel AG. Additionally, Calliditas is conducting a Phase 2b/3 objective proceedings successful superior biliary cholangitis and a Phase 2 proof-of-concept proceedings successful caput and cervix crab with its NOX inhibitor merchandise candidate, setanaxib. Calliditas' communal shares are listed connected Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed connected the Nasdaq Global Select Market (ticker: CALT).
The pursuing files are disposable for download:
Cision
View archetypal content:https://www.prnewswire.co.uk/news-releases/key-opinion-leader-fireside-chat-with-professor-richard-lafayette-on-the-us-igan-treatment-landscape-301669913.html
English (US)